2024 2023 2024.11.29 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION REACHED PRIMARY ENDPOINT 2024.11.28 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA WERE PRESENTED AT THE 19TH CDA ANNUAL MEETING 2024.11.18 VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR 2024.11.12 VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2024.11.11 VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR 2024.10.31 OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024 2024.10.31 Next Day Disclosure Return 2024.10.31 VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK 2024.10.22 Next Day Disclosure Return 2024.10.21 Next Day Disclosure Return 2024.10.18 Next Day Disclosure Return 2024.10.17 VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR 2024.10.17 Next Day Disclosure Return 2024.10.15 Next Day Disclosure Return 2024.10.14 VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR 2024.10.10 Next Day Disclosure Return 2024.10.09 VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR 2024.10.09 Next Day Disclosure Return 2024.10.08 VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR 2024.10.08 Next Day Disclosure Return 2024.10.07 Next Day Disclosure Return 2024.10.04 Next Day Disclosure Return 2024.10.03 Next Day Disclosure Return 2024.09.30 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION 2024.09.27 VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS 2024.09.27 Next Day Disclosure Return 2024.09.26 Next Day Disclosure Return 2024.09.25 Next Day Disclosure Return 2024.09.23 Next Day Disclosure Return 2024.09.20 Next Day Disclosure Return 2024.09.02 SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT 2024.08.29 INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 2024.08.29 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 8TH ANNUAL MEETING OF CHINESE HAIR RESEARCH SOCIETY 2024.08.19 DATE OF BOARD MEETING 2024.07.31 VOLUNTARY ANNOUNCEMENT - DRUG MARKETING AUTHORIZATION APPLICATION FOR CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2024.07.30 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED ONLINE IN THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 2024.07.23 Next Day Disclosure Return 2024.07.18 Next Day Disclosure Return 2024.07.17 Next Day Disclosure Return 2024.07.16 Next Day Disclosure Return 2024.07.12 VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PROGRAM UNDER THE SHARE REPURCHASE MANDATE 2024.06.28 VOLUNTARY ANNOUNCEMENT - LAST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION 2024.06.28 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 29TH ANNUAL MEETING OF CSD 2024.06.27 OPERATIONAL UPDATE FOR THE FIRST QUARTER OF 2024 2024.06.05 POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024 2024.05.31 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PRESENTED AT THE 13TH ADC 2024.05.30 VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS APPROVED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2024.04.30 VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) IN HONG KONG, PRC 2024.04.30 VOLUNTARY ANNOUNCEMENT - A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY OBTAINED THE "DRUG MANUFACTURING CERTIFICATE" ISSUED BY THE JIANGSU MEDICAL PRODUCTS ADMINISTRATION 2024.04.26 FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 5 JUNE 2024 2024.04.26 NOTICE OF ANNUAL GENERAL MEETING 2024.04.26 (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES (3) PROPOSED RE-APPOINTMENT OF AUDITOR AND (4) NOTICE OF ANNUAL GENERAL MEETING 2024.03.27 ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 2024.03.27 VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2024.03.18 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN FTSE GLOBAL EQUITY INDEX SERIES 2024.03.15 DATE OF BOARD MEETING 2024.02.29 OPERATIONAL UPDATE FOR THE YEAR ENDED 31 DECEMBER 2023 AND FOURTH QUARTER OF 2023 2024.02.28 VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION IN CHINA 2024.02.20 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES 2024.01.31 VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2024.01.31 VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA REACHED PRIMARY ENDPOINT 2024.01.03 VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION 2023.12.11 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING 2023.11.27 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK 2023.11.06 OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 AND THIRD QUARTER OF 2023 2023.11.02 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT 2023.10.25 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION 2023.09.27 VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2023.09.07 VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) REACHED PRIMARY ENDPOINT 2023.09.05 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN THE LIST FOR SOUTHBOUND TRADING LINK UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT 2023.08.29 INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023 2023.08.28 DISCLOSEABLE TRANSACTIONS - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS 2023.08.28 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK 2023.08.23 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) 2023.08.18 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES 2023.08.17 DATE OF BOARD MEETING 2023.08.10 VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) HAS BEEN GRANTED PRIORITY REVIEW DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION 2023.08.02 OPERATIONAL UPDATE FOR THE SECOND QUARTER AND FIRST HALF OF 2023 2023.07.18 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) 2023.07.05 STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION 2023.06.09 LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS 2023.06.09 Terms of Reference for the Nomination Committee 2023.06.09 Terms of Reference for the Remuneration Committee 2023.06.09 Terms of Reference for the Audit Committee 2023.06.09 ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS 2023.05.31 GLOBAL OFFERING 2023.05.31 GREEN APPLICATION FORM 2023.05.31 GLOBAL OFFERING (Multi-Files) 2023.05.31 GLOBAL OFFERING
